Melanoma in situ: Part II. Histopathology, treatment, and clinical management
- PMID: 26183968
- DOI: 10.1016/j.jaad.2015.03.057
Melanoma in situ: Part II. Histopathology, treatment, and clinical management
Abstract
Melanoma in situ (MIS) poses special challenges with regard to histopathology, treatment, and clinical management. The negligible mortality and normal life expectancy associated with patients with MIS should guide treatment for this tumor. Similarly, the approach to treatment should take into account the potential for MIS to transform into invasive melanoma, which has a significant impact on morbidity and mortality. Part II of this continuing medical education article reviews the histologic features, treatment, and management of MIS.
Keywords: lentigo maligna; melanoma; melanoma in situ.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Metastatic melanoma - a review of current and future treatment options.Acta Derm Venereol. 2015 May;95(5):516-24. doi: 10.2340/00015555-2035. Acta Derm Venereol. 2015. PMID: 25520039 Review.
-
Cutaneous melanoma: detecting it earlier, weighing management options.J Fam Pract. 2007 Jan;56(1):18-28. J Fam Pract. 2007. PMID: 17217894 Review. No abstract available.
-
Melanoma in situ: Part I. Epidemiology, screening, and clinical features.J Am Acad Dermatol. 2015 Aug;73(2):181-90, quiz 191-2. doi: 10.1016/j.jaad.2015.04.014. J Am Acad Dermatol. 2015. PMID: 26183967 Review.
-
Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.Int J Dermatol. 2010 May;49(5):482-91. doi: 10.1111/j.1365-4632.2010.04423.x. Int J Dermatol. 2010. PMID: 20534080 Review.
-
Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ.Dermatol Surg. 2013 Mar;39(3 Pt 1):365-71. doi: 10.1111/dsu.12078. Epub 2013 Jan 28. Dermatol Surg. 2013. PMID: 23356872
Cited by
-
Topical and Intralesional Immunotherapy for Melanoma In Situ: A Review.Cancers (Basel). 2023 Sep 8;15(18):4468. doi: 10.3390/cancers15184468. Cancers (Basel). 2023. PMID: 37760438 Free PMC article. Review.
-
Topical Calcipotriol Plus Imiquimod Immunotherapy for Nonkeratinocyte Skin Cancers.JID Innov. 2023 Aug 12;3(6):100221. doi: 10.1016/j.xjidi.2023.100221. eCollection 2023 Nov. JID Innov. 2023. PMID: 37731472 Free PMC article.
-
Anticancer Effect of Cold Atmospheric Plasma in Syngeneic Mouse Models of Melanoma and Colon Cancer.Molecules. 2023 May 18;28(10):4171. doi: 10.3390/molecules28104171. Molecules. 2023. PMID: 37241912 Free PMC article.
-
Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses.Nat Biomed Eng. 2023 Sep;7(9):1081-1096. doi: 10.1038/s41551-023-01031-3. Epub 2023 Apr 24. Nat Biomed Eng. 2023. PMID: 37095318
-
Is It Time to Supersede the Diagnostic Term "Melanoma In Situ with Regression?" A Narrative Review.Dermatopathology (Basel). 2023 Mar 22;10(1):120-127. doi: 10.3390/dermatopathology10010018. Dermatopathology (Basel). 2023. PMID: 36975387 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
